Adjuvant chemoradiotherapy versus chemotherapy alone in stage III endometrial cancer: A systematic review and meta‐analysis. Issue 7 (5th April 2022)

• Record Type: Journal Article
• Authors: Zhang, Guo; Li, He; Tian, Zhao; Li, Xiaoping; Wang, Zhiqi; Liang, Xudong; Wang, Yue; Shen, Xiaoyan; Wang, Jianliu
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 48:Issue 7(2022)
• Page Start: 1888
• Page End: 1896
• Publication Date: 2022-04-05
• Subjects: chemoradiotherapy -- chemotherapy -- endometrial cancer -- overall survival -- relapse‐free survival; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.15238
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Objective: To discuss the impact of chemoradiotherapy (CRT) on the survival of patients with stage III endometrial cancer (EC) compared with chemotherapy (CT) alone. Methods: Articles involving adjuvant CRT versus CT on survival in stage III EC were retrieved from PubMed and EMBASE. Hazard ratios (HRs) of overall survival (OS) and relapse‐free survival (RFS) were collected and pooled, and publication bias was measured by Begg's and Egger's test. Quality of researches was measured by the Newcastle–Ottawa scale and the modified Jadad scale. Results: Eleven were included in the statistical analysis. A significant advantage of CRT over CT on OS was shown (HR 0.59, 95% CI 0.49–0.70). Further subgroup analysis suggested the advantage was mostly associated with stage IIIC (HR 0.63, 95% CI 0.52, 0.76]). A similar result favoring CRT was also reached on RFS (HR 0.66, 95% CI 0.47–0.93). No significant publication bias was observed. Conclusion: CRT was associated with a better OS and RFS than CT alone in stage III EC patients.